APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pimozide

Pimozide (sold under the brand name Orap) is an antipsychotic drug of the diphenylbutylpiperidine class. It was discovered at Janssen Pharmaceutica in 1963. It has a high potency compared to chlorpromazine (ratio 50-70:1). On a weight basis it is even more potent than haloperidol. It also has special neurologic indications for Tourette syndrome and resistant tics. The side effects include akathisia, tardive dyskinesia, and, more rarely, neuroleptic malignant syndrome and prolongation of the QT interval.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Pimozide (sold under the brand name Orap) is an antipsychotic drug of the diphenylbutylpiperidine class. It was discovered at Janssen Pharmaceutica in 1963. It has a high potency compared to chlorpromazine (ratio 50-70:1). On a weight basis it is even more potent than haloperidol. It also has special neurologic indications for Tourette syndrome and resistant tics. The side effects include akathisia, tardive dyskinesia, and, more rarely, neuroleptic malignant syndrome and prolongation of the QT interval.

Selected research

Market Outlook & Growth Opportunities

Global Pimozide Market Outlook and Growth Opportunities 2026

Report ID 174025790426 December 2025197 pages

Choose your research edition.

Industry ResearchPimozide Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Pimozide Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Pimozide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pimozide Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Pimozide Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Pimozide (sold under the brand name Orap) is an antipsychotic drug of the diphenylbutylpiperidine class. It was discovered at Janssen Pharmaceutica in 1963. It has a high potency compared to chlorpromazine (ratio 50-70:1). On a weight basis it is even more potent than haloperidol. It also has special neurologic indications for Tourette syndrome and resistant tics. The side effects include akathisia, tardive dyskinesia, and, more rarely, neuroleptic malignant syndrome and prolongation of the QT interval.

Global Pimozide key players include Teva, Par Pharmaceutical, Johnson & Johnson, etc. Global top three manufacturers hold a share about 80%.

North America is the largest market, with a share about 40%, followed by Europe and South America, both have a share about 45 percent.

Read the full market overview

In terms of product, 2Mg is the largest segment, with a share over 50%. And in terms of application, the largest application is Hospitals, followed by Drugstores, etc.

This report provides an overview of the global Pimozide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pimozide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pimozide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pimozide market size, projected growth trends, production technologies, key applications, and end-use industries.

Pimozide Segment by Company

Teva

Par Pharmaceutical

Johnson & Johnson

Eumedica

Pharmascience

Domina Pharmaceuticals

Aa Pharma

Pimozide Segment by Type

1Mg

2Mg

4Mg

Pimozide Segment by Application

Hospitals

Drugstores

Others

Pimozide Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pimozide status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pimozide market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pimozide significant trends, drivers, influence factors in global and regions.

6. To analyze Pimozide competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pimozide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pimozide and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pimozide.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pimozide market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pimozide industry.

Chapter 3: Detailed analysis of Pimozide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pimozide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pimozide in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pimozide Industry Trends Table 2. Pimozide Industry Drivers Table 3. Pimozide Industry Opportunities and Challenges Table 4. Pimozide Industry Restraints Table 5. Global Pimozide Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pimozide Revenue Share by Company (2021-2026) Table 7. Global Pimozide Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Pimozide Sales Volume Share by Company (2021-2026) Table 9. Global Pimozide Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Pimozide Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pimozide Key Company Manufacturing Base & Headquarters Table 12. Global Pimozide Company, Product Type & Application Table 13. Global Pimozide Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pimozide by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 1Mg Table 18. Significant Companies of 2Mg Table 19. Significant Companies of 4Mg Table 20. Global Pimozide Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Pimozide Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Pimozide Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Pimozide Sales Volume Share by Type (2021-2026) Table 24. Global Pimozide Sales Volume Share by Type (2027-2032) Table 25. Global Pimozide Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Pimozide Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Pimozide Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Pimozide Sales Value Share by Type (2021-2026) Table 29. Global Pimozide Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospitals Table 31. Significant Companies of Drugstores Table 32. Significant Companies of Others Table 33. Global Pimozide Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Pimozide Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Pimozide Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Pimozide Sales Volume Share by Application (2021-2026) Table 37. Global Pimozide Sales Volume Share by Application (2027-2032) Table 38. Global Pimozide Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Pimozide Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Pimozide Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Pimozide Sales Value Share by Application (2021-2026) Table 42. Global Pimozide Sales Value Share by Application (2027-2032) Table 43. Global Pimozide Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Pimozide Sales by Region (2021-2026) & (K Units) Table 45. Global Pimozide Sales Market Share by Region (2021-2026) Table 46. Global Pimozide Sales by Region (2027-2032) & (K Units) Table 47. Global Pimozide Sales Market Share by Region (2027-2032) Table 48. Global Pimozide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Pimozide Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Pimozide Sales Value Share by Region (2021-2026) Table 51. Global Pimozide Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Pimozide Sales Value Share by Region (2027-2032) Table 53. Global Pimozide Market Average Price (USD/Unit) by Region (2021-2026) Table 54. Global Pimozide Market Average Price (USD/Unit) by Region (2027-2032) Table 55. Global Pimozide Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Pimozide Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Pimozide Sales by Country (2021-2026) & (K Units) Table 58. Global Pimozide Sales Market Share by Country (2021-2026) Table 59. Global Pimozide Sales by Country (2027-2032) & (K Units) Table 60. Global Pimozide Sales Market Share by Country (2027-2032) Table 61. Global Pimozide Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Pimozide Sales Value Market Share by Country (2021-2026) Table 63. Global Pimozide Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Pimozide Sales Value Market Share by Country (2027-2032) Table 65. Teva Company Information Table 66. Teva Business Overview Table 67. Teva Pimozide Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 68. Teva Pimozide Product Portfolio Table 69. Teva Recent Development Table 70. Par Pharmaceutical Company Information Table 71. Par Pharmaceutical Business Overview Table 72. Par Pharmaceutical Pimozide Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 73. Par Pharmaceutical Pimozide Product Portfolio Table 74. Par Pharmaceutical Recent Development Table 75. Johnson & Johnson Company Information Table 76. Johnson & Johnson Business Overview Table 77. Johnson & Johnson Pimozide Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 78. Johnson & Johnson Pimozide Product Portfolio Table 79. Johnson & Johnson Recent Development Table 80. Eumedica Company Information Table 81. Eumedica Business Overview Table 82. Eumedica Pimozide Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 83. Eumedica Pimozide Product Portfolio Table 84. Eumedica Recent Development Table 85. Pharmascience Company Information Table 86. Pharmascience Business Overview Table 87. Pharmascience Pimozide Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 88. Pharmascience Pimozide Product Portfolio Table 89. Pharmascience Recent Development Table 90. Domina Pharmaceuticals Company Information Table 91. Domina Pharmaceuticals Business Overview Table 92. Domina Pharmaceuticals Pimozide Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 93. Domina Pharmaceuticals Pimozide Product Portfolio Table 94. Domina Pharmaceuticals Recent Development Table 95. Aa Pharma Company Information Table 96. Aa Pharma Business Overview Table 97. Aa Pharma Pimozide Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 98. Aa Pharma Pimozide Product Portfolio Table 99. Aa Pharma Recent Development Table 100. Key Raw Materials Table 101. Raw Materials Key Suppliers Table 102. Pimozide Distributors List Table 103. Pimozide Customers List Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Pimozide Product Image Figure 2. Global Pimozide Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pimozide Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pimozide Sales (2021-2032) & (K Units) Figure 5. Global Pimozide Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Pimozide Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 1Mg Image Figure 10. 2Mg Image Figure 11. 4Mg Image Figure 12. Global Pimozide Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Pimozide Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Pimozide Sales Volume Share by Type (2021-2032) Figure 15. Global Pimozide Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Pimozide Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Pimozide Sales Value Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Drugstores Image Figure 20. Others Image Figure 21. Global Pimozide Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Pimozide Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Pimozide Sales Volume Share by Application (2021-2032) Figure 24. Global Pimozide Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Pimozide Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Pimozide Sales Value Share by Application (2021-2032) Figure 27. Global Pimozide Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Pimozide Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Pimozide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Pimozide Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Pimozide Sales Value (2021-2032) & (US$ Million) Figure 32. North America Pimozide Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Pimozide Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Pimozide Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Pimozide Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Pimozide Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Pimozide Sales Value (2021-2032) & (US$ Million) Figure 38. South America Pimozide Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Pimozide Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Pimozide Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Pimozide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Pimozide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Pimozide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Pimozide Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Pimozide Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 1Mg
  • 2Mg
  • 4Mg
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Teva
  • Par Pharmaceutical
  • Johnson & Johnson
  • Eumedica
  • Pharmascience
  • Domina Pharmaceuticals
  • Aa Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pimozide Sales Value (2021-2032)
  4. 1.2.2 Global Pimozide Sales Volume (2021-2032)
  5. 1.2.3 Global Pimozide Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pimozide Market Dynamics
  1. 2.1 Pimozide Industry Trends
  2. 2.2 Pimozide Industry Drivers
  3. 2.3 Pimozide Industry Opportunities and Challenges
  4. 2.4 Pimozide Industry Restraints
3 Pimozide Market by Company
  1. 3.1 Global Pimozide Company Revenue Ranking in 2025
  2. 3.2 Global Pimozide Revenue by Company (2021-2026)
  3. 3.3 Global Pimozide Sales Volume by Company (2021-2026)
  4. 3.4 Global Pimozide Average Price by Company (2021-2026)
  5. 3.5 Global Pimozide Company Ranking (2024-2026)
  6. 3.6 Global Pimozide Company Manufacturing Base and Headquarters
  7. 3.7 Global Pimozide Company Product Type and Application
  8. 3.8 Global Pimozide Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pimozide Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pimozide Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pimozide Market by Type
  1. 4.1 Pimozide Type Introduction
  2. 4.1.1 1Mg
  3. 4.1.2 2Mg
  4. 4.1.3 4Mg
  5. 4.2 Global Pimozide Sales Volume by Type
  6. 4.2.1 Global Pimozide Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pimozide Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Pimozide Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Pimozide Sales Value by Type
  10. 4.3.1 Global Pimozide Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Pimozide Sales Value by Type (2021-2032)
  12. 4.3.3 Global Pimozide Sales Value Share by Type (2021-2032)
5 Pimozide Market by Application
  1. 5.1 Pimozide Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Drugstores
  4. 5.1.3 Others
  5. 5.2 Global Pimozide Sales Volume by Application
  6. 5.2.1 Global Pimozide Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pimozide Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Pimozide Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Pimozide Sales Value by Application
  10. 5.3.1 Global Pimozide Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pimozide Sales Value by Application (2021-2032)
  12. 5.3.3 Global Pimozide Sales Value Share by Application (2021-2032)
6 Pimozide Regional Sales and Value Analysis
  1. 6.1 Global Pimozide Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pimozide Sales by Region (2021-2032)
  3. 6.2.1 Global Pimozide Sales by Region: 2021-2026
  4. 6.2.2 Global Pimozide Sales by Region (2027-2032)
  5. 6.3 Global Pimozide Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pimozide Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pimozide Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pimozide Sales Value by Region (2027-2032)
  9. 6.5 Global Pimozide Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pimozide Sales Value (2021-2032)
  12. 6.6.2 North America Pimozide Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pimozide Sales Value (2021-2032)
  15. 6.7.2 Europe Pimozide Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pimozide Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pimozide Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pimozide Sales Value (2021-2032)
  21. 6.9.2 South America Pimozide Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pimozide Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pimozide Sales Value Share by Country, 2025 VS 2032
7 Pimozide Country-level Sales and Value Analysis
  1. 7.1 Global Pimozide Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pimozide Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pimozide Sales by Country (2021-2032)
  4. 7.3.1 Global Pimozide Sales by Country (2021-2026)
  5. 7.3.2 Global Pimozide Sales by Country (2027-2032)
  6. 7.4 Global Pimozide Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pimozide Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pimozide Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pimozide Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pimozide Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pimozide Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pimozide Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pimozide Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pimozide Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pimozide Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pimozide Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pimozide Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pimozide Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pimozide Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pimozide Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pimozide Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pimozide Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pimozide Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pimozide Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pimozide Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pimozide Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pimozide Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pimozide Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pimozide Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pimozide Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pimozide Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pimozide Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pimozide Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pimozide Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pimozide Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pimozide Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pimozide Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pimozide Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pimozide Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pimozide Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pimozide Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pimozide Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pimozide Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pimozide Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pimozide Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pimozide Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pimozide Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pimozide Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pimozide Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pimozide Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pimozide Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pimozide Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pimozide Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pimozide Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pimozide Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pimozide Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pimozide Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pimozide Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pimozide Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pimozide Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pimozide Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pimozide Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pimozide Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pimozide Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pimozide Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pimozide Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pimozide Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pimozide Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pimozide Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pimozide Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pimozide Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pimozide Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pimozide Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pimozide Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pimozide Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pimozide Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pimozide Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pimozide Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pimozide Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pimozide Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pimozide Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pimozide Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pimozide Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pimozide Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pimozide Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pimozide Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pimozide Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pimozide Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pimozide Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pimozide Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pimozide Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pimozide Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Pimozide Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pimozide Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Par Pharmaceutical
  8. 8.2.1 Par Pharmaceutical Company Information
  9. 8.2.2 Par Pharmaceutical Business Overview
  10. 8.2.3 Par Pharmaceutical Pimozide Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Par Pharmaceutical Pimozide Product Portfolio
  12. 8.2.5 Par Pharmaceutical Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Pimozide Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Pimozide Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Eumedica
  20. 8.4.1 Eumedica Company Information
  21. 8.4.2 Eumedica Business Overview
  22. 8.4.3 Eumedica Pimozide Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Eumedica Pimozide Product Portfolio
  24. 8.4.5 Eumedica Recent Developments
  25. 8.5 Pharmascience
  26. 8.5.1 Pharmascience Company Information
  27. 8.5.2 Pharmascience Business Overview
  28. 8.5.3 Pharmascience Pimozide Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pharmascience Pimozide Product Portfolio
  30. 8.5.5 Pharmascience Recent Developments
  31. 8.6 Domina Pharmaceuticals
  32. 8.6.1 Domina Pharmaceuticals Company Information
  33. 8.6.2 Domina Pharmaceuticals Business Overview
  34. 8.6.3 Domina Pharmaceuticals Pimozide Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Domina Pharmaceuticals Pimozide Product Portfolio
  36. 8.6.5 Domina Pharmaceuticals Recent Developments
  37. 8.7 Aa Pharma
  38. 8.7.1 Aa Pharma Company Information
  39. 8.7.2 Aa Pharma Business Overview
  40. 8.7.3 Aa Pharma Pimozide Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Aa Pharma Pimozide Product Portfolio
  42. 8.7.5 Aa Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pimozide Value Chain Analysis
  2. 9.1.1 Pimozide Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pimozide Sales Mode & Process
  6. 9.2 Pimozide Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pimozide Distributors
  9. 9.2.3 Pimozide Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst